logo

For the Inventor, By the Inventor

Tokyo, Japan

Eisai R&D Management Co., Ltd.

Calculating rank
USPTO Granted Patents = 13


Forward Citations = 0

Loading Chart...
Loading Chart...

106 inventors (with patents filed for the assignee):

goldMedal Thiwanka Samarakoon (2 out of 8 patents)

silverMedal Sudeep Prajapati (2 out of 15 patents)

bronzeMedal James Palacino (2 out of 10 patents)

4.  Andrew Cook (2 out of 22 patents)

5.  Xiang Liu (2 out of 10 patents)

6.  Jason T Lowe (1 out of 14 patents)

7.  Cheng Zhong (1 out of 15 patents)

8.  Shelby Ellery (1 out of 7 patents)

9.  Megan Sheehan (1 out of 6 patents)

10.  Stephanos Ioannidis (1 out of 40 patents)

11.  Jun Takahashi (1 out of 17 patents)

12.  Yusuke Miyashita (1 out of 5 patents)

13.  Hirofumi Kuroda (1 out of 7 patents)

14.  Jared Spidel (1 out of 14 patents)

15.  Kiyotoshi Sekiguchi (1 out of 18 patents)


13 patents:

1. 12734161 - METHOD OF TREATING BREAST CANCER (2026-09-15),
2. 12729191 - Production method for synthetic intermediate of monocyclic pyridine derivative (2026-09-08),
3. 12721851 - Pharmaceutical composition for treating solid tumors (2026-09-01),
4. 12702660 - Method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor (2026-08-11),
5. 12661398 - COMBINATION OF A PD-1 ANTAGONIST, A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND A CBP/BETA-CATENIN INHIBITOR FOR TREATING CANCER (2026-06-23),
6. 12630544 - Compound, α-synuclein aggregate binder, and use thereof (2026-05-19),
7. 12622905 - ARYL PLADIENOLIDES FOR THE TREATMENT OF NEOPLASTIC DISORDERS (2026-05-12),
8. 12606541 - PPARg modulators and methods of use (2026-04-21),
9. 12564641 - ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE (2026-03-03),
10. 12564600 - System for enhancing therapeutic compliance of the anti-cancer compound E7766 (2026-03-03),
11. 12545894 - METHOD FOR INDUCING DOPAMINERGIC NEURON PROGENITOR CELLS (2026-02-10),
12. 12545675 - Anti-wolbachia pyrido[2,3-d]pyrimidine compounds (2026-02-10),
13. 12514928 - HERBOXIDIENE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE (2026-01-06),
Company Overview
Eisai R&D Management Co., Ltd., based in Tokyo, specializes in the research and development of innovative pharmaceuticals. The company focuses on addressing unmet medical needs, particularly in areas such as neurology and oncology. With a commitment to advancing healthcare, Eisai emphasizes collaboration and scientific excellence in its research initiatives. The organization is dedicated to developing therapies that improve patient outcomes and enhance quality of life, leveraging cutting-edge technologies and methodologies in its R&D processes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

13 Patents

#1,665 in TOKYO

#3,754 in Japan

#45,104 in the World

Tokyo, JP
Tokyo, Japan

Eisai R&D Management Co., Ltd.

Forward Citations = 0

106 inventors:

goldMedal Thiwanka Samarakoon (2 out of 8 patents)

silverMedal Sudeep Prajapati (2 out of 15 patents)

bronzeMedal James Palacino (2 out of 10 patents)

4.  Andrew Cook (2 out of 22 patents)

5.  Xiang Liu (2 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Eisai R&D Management Co., Ltd.. Retrieved from https://idiyas.com/company/eisai-r-and-d-management

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…